Effect of amifostine on neuroblastoma during high dose chemotherapy: In vivo and in vitro investigations

Anticancer Research

Volumn 20, Issue 6 B, 2000, Pages 4531-4538

  Renner, S ^a   Krumpelmann S ^a   Bruchelt, G ^a   Wiesinger, H ^a   Niethammer, D ^a   Klingebiel, T ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Amifostine; Carboplatin; High dose chemotherapy; Melphalan; Neuroblastoma; Polyamine transporter; VP 16

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; CARBOPLATIN; ETOPOSIDE; MELPHALAN; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; ARTIFICIAL VENTILATION; BLOOD TOXICITY; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CELL PROTECTION; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROBLASTOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIRUBIN; CARBOPLATIN; CASE-CONTROL STUDIES; CHILD; CREATININE; DRUG INTERACTIONS; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATION; MELPHALAN; NEOPLASM STAGING; NEUROBLASTOMA; RATS; RESPIRATORY MUCOSA; TUMOR CELLS, CULTURED; VOMITING;

EID: 0034477112     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Amifostine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutical potential as a radioprotector and cytotoxic chemoprotector
2. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): Preclinical aspects
3. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: Clinical experiences
4. Direct amifostine effect on renal tubule cells in rats
5. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial
6. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors
7. The potential role of amifostine (Ethyol®) in haematological malignancies
8. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas
9. Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies
10. The preclinical basis for broad-spectrum selective cytoprotection of normal tissue from cytotoxic therapies by amifostine
11. Pharmacokinetic profile of amifostine
12. Biochemical determinants of the cytoprotective effect of amifostine
13. Uptake of WR-2721 Derivatives by cells in culture: Identification of the transported form of the drug
14. Reducing the toxicity of anticancer therapy: New strategies
15. Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278
16. Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children
17. 131I-meta-iodo-benzyl-guanidine, highdose chemotherapy and immunotherapy. A pilot study
18. Human pharmacokinetics of WR-2721
19. Pharmacokinetics of WR-2721
20. Primary glial cultures as a model for studying hormone action
21. Rapid colorimetric assay for cellular growth and cytotoxicity assays
22. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer
23. Future development of amifostine in cancer treatment
24. Administration of Ethyol (amifostine) in a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin
25. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with ovarian cancer
26. Chemoprotectants: A review of their clinical pharmacology and therapeutical efficacy
27. Safety and efficacy of amifostine in children to prevent myelotoxicity of high dose carboplatin: Preliminary results of a cooperative phase I-II clinical trial
28. Randomized versus historical controls for clinical trials
29. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro
30. WR-1065, the active metabolite of amifostine (Ethyol"), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
31. The effects of cycloheximide and WR-1065 on radiation-induced repair processes: A mechanism for chemoprevention
32. Radioprotectants: Pharmacology and clinical applications of amifostine
33. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721
34. Isotachophoretic determination of phosphate splitting from amifostine and p-nitrophenyl- phosphate in serum and neuroblastoma cells
35. Transport of polyamines in glial cells
36. Radioprotection of cells in culture by WR-2721 and derivatives: Form of the drug responsible for protection
37. Amifostine: Potential for clinically useful cytoprotection
38. Preclinical evaluation of WR-151327: An orally active chemotherapy protector
39. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: A randomised phase II study
40. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
41. Effects of the modulating agent WR 2721 on myelotoxicity and activity in carboplatin-treated mice